Evidence map›Paper›PMID 41170389›Full record

ArticleFrontiers in pharmacology2025

Efficacy and safety of live combined

Wenwen Li, Yingying Liang, Guangcai Li, Dandan Yang, Xiaoqian Zhang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenwen LiDepartment of Gastroenterology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China.
Yingying LiangDepartment of Gastroenterology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China.
Guangcai LiDepartment of Gastroenterology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China.
Dandan YangDepartment of Gastroenterology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China.
Xiaoqian ZhangDepartment of Gastroenterology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Live combined Methods: Randomized controlled trials (RCTs) assessing the efficacy or safety of LCBE in patients with constipation, published before September 2025, were comprehensively searched for in Wan Fang, China National Knowledge Infrastructure, China Science and Technology Journal Database, Web of Science, Cochrane Library, and PubMed. Efficacy and safety outcomes were extracted. Results: A total of 32 studies were included, containing 1,565 patients receiving LCBE and control treatment (experimental group) and 1,490 patients receiving control treatment alone (control group). The experimental group showed a higher total effective rate [odds ratio (OR) (95% confidence interval (CI)) = 5.789 (4.598-7.288); Conclusion: LCBE demonstrates a favorable efficacy and good tolerability in patients with constipation. This meta-analysis provides supportive evidence for its clinical application in the management of constipation.

Indexed as

constipationefficacylive combined Bacillus subtilis and Enterococcus faeciummeta-analysissafety

Identifiers

PMID41170389
PMCPMC12569391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.